Cyclica, a leading biotechnology company that commercialized Ligand Express announced its novel, first-in-class drug design technology, Ligand Design on stage at the Collision Conference in Toronto.
US-based drugmaker Amgen has agreed to acquire Denmark-based small molecule drug discovery platform biotech firm Nuevolution for around $167m (£132m).
Merck has signed an agreement to acquire Peloton Therapeutics, a US-based clinical-stage biopharmaceutical firm, in a deal valued at around $2.2bn (£1.72bn).
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP).
ESSA Pharma announced that it has entered into a definitive agreement with Realm Therapeutics setting forth the terms of an acquisition whereby ESSA will acquire all of the issued and outstanding shares of Realm in an all-stock transaction.
Takeda Pharmaceutical and Frazier Healthcare Partners have announced a collaboration to launch Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders.
A new biotechnology holding company in the form of ElevateBio has been launched in Cambridge, Massachusetts with an objective to develop a portfolio of cell and gene therapy companies.
Zymeworks has entered into a licensing agreement that grants Iconic Therapeutics non-exclusive rights to Zymeworks’ proprietary ZymeLink antibody-drug conjugate (ADC) platform for the development of its ICON-2 Tissue Factor ADC for cancer.
Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the closure of an asset purchase and license agreement with ImmunGene, a privately held biotechnology company.
Magenta Therapeutics, a clinical-stage biotechnology company, announced that the company presented Phase 2 clinical data on its cell therapy, MGTA-456, at the annual meeting of the American Academy of Neurology in Philadelphia, Pennsylvania.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.